Compare BXMT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXMT | AUPH |
|---|---|---|
| Founded | 1966 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 1998 | 2014 |
| Metric | BXMT | AUPH |
|---|---|---|
| Price | $10.48 | $16.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $17.43 | ★ $17.86 |
| AVG Volume (30 Days) | ★ 3.0M | 772.2K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 17.44% | N/A |
| EPS Growth | 154.70 | ★ 5075.00 |
| EPS | N/A | ★ 0.53 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $15.83 |
| Revenue Next Year | N/A | $21.30 |
| P/E Ratio | ★ N/A | $31.55 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $10.49 | $11.39 |
| 52 Week High | $20.67 | $19.25 |
| Indicator | BXMT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 22.71 | 54.37 |
| Support Level | N/A | $15.61 |
| Resistance Level | $19.62 | $17.02 |
| Average True Range (ATR) | 0.35 | 0.42 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 4.18 | 59.18 |
Blackstone Mortgage Trust Inc is an externally managed real estate finance company that originates, acquires, and manages senior loans and other debt or credit-oriented investments collateralized by or relating to commercial real estate in North America, Europe, and Australia. Its portfolio is composed of senior loans secured by high-quality, institutional assets located in main markets, and sponsored by experienced, well-capitalized real estate investment owners and operators. The group finances its investments in a variety of ways, including borrowing under secured credit facilities, issuing collateralized loan obligations, or CLOs, other securitization transactions, syndicating senior loans and/or participations, and other forms of asset-level financing.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.